Biopharmaceuticals and Middle Molecule Drugs have been rapidly growing in the market in recent years. SPERA PHARMA also possesses analytical capability for Biopharmaceuticals and Middle Molecule Drugs.
SPERA PHARMA offers analytical method development and validation for quality control of biopharmaceuticals, including antibody drugs, and middle molecule drugs, such as oligonucleotides and peptides, as well as the release tests for clinical trial materials. SPERA also possesses capability to conduct stability studies to assure stability of these drugs.
Since biopharmaceuticals and middle molecule drugs have complexed heterogeneity, characterizations are essential to assure the safety and efficacy. In addition, in the case that manufacturing procedures, scales, and formulation for DS/DP are changed, comparability evaluation before and after the change should be performed.
SPERA offers characterization and comparability evaluation between lots, which are especially important for biopharmaceuticals and middle molecule drugs development. SPERA will select and evaluate optimal analytical methods and support your drug development.
Our principle analytical services are listed below.
SPERA provides CMC solutions from early-stage through new drug application.
Contact USpage top